Why Aceragen (ACGN) Stock Is Down 30% Today

8/7/23 10:34:15 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ACGN alert in real time by email

Aceragen, Inc. (NASDAQ:ACGN) shares are trading lower by 30% to $0.53 Monday morning after the company announced it will delist from the Nasdaq.

The company says the delisting process will be orderly and subject to stockholder approval of the Assignment Proposal at a special meeting scheduled for August 14.

The decision follows the company's plans to seek stockholder approval for a transfer and assignment of most of its assets to an assignee for the benefit of creditors, as previously disclosed.

According to data from Benzinga Pro, ACGN has a 52-week high of $16.00 and a 52-week low of $0.46.

Get the next $ACGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACGN

Date	Price Target	Rating	Analyst

More analyst ratings

$ACGN
Press Releases

Fastest customizable press release news feed in the world

Aceragen, Inc. to Delist from The Nasdaq Stock Market
DURHAM, N.C. and EXTON, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the "Company") (NASDAQ:ACGN), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Capital Market ("Nasdaq") by filing a Form 25 with the Securities and Exchange Commission (the "SEC") on or about August 15, 2023. As previously disclosed, on August 14, 2023, the Company expects to hold a special meeting seeking stockholder approval to effect a transfer and assignment of substantially all of the Company's assets to an assignee for the benefit of creditors (the "Assignment Proposal"). Subject to stockholder approval of the Assignment Proposal, and in order
8/4/23 4:30:00 PM ET
$ACGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
DURHAM, N.C. and EXTON, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the "Company") (NASDAQ:ACGN), announced today that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Global Market. The Company has until July
5/30/23 4:25:00 PM ET
$ACGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study
DURHAM, N.C. and EXTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (NASDAQ:ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification. The DMC review was a planned meeting held in order to monitor the safety of the seriously ill subjects participating in the TERRA study.
2/6/23 9:25:00 AM ET
$ACGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ACGN
Market Insights

Live Market Insights

12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Vistagen Therapeutics (NASDAQ:VTGN) stock rose 22.5% to $8.62 during Wednesday's after-market session. Trading volume for this security closed at 4.6 million, accounting for 394.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $68.8 million. AIM ImmunoTech (AMEX:AIM) shares rose 11.69% to $0.64. The market value of their outstanding shares is at $30.7 million. Tenon Medical (NASDAQ:TNON) shares moved upwards by 10.45% to $0.26. Tenon Medical's trading volume hit 156.5K shares by close, accounting for 23.3% of its average volume over the last 100 days. The company's market cap stands at $5.6 million. The company's, Q2 earn
8/9/23 5:32:20 PM ET
$ACGN
$AHG
$GRTX
$INFI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Business Services
Consumer Discretionary
Axogen shares are trading lower after the company reported worse-than-expected Q2 revenue results and maintained FY23 revenue guidance.
8/8/23 11:49:50 AM ET
$ACGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Vistagen Therapeutics (NASDAQ:VTGN) shares rose 871.4% to $16.32 during Monday's regular session. Trading volume for this security as of 13:30 EST is 40.9 million, which is 18764.9% of its average full-day volume over the last 100 days. The company's market cap stands at $130.3 million. Nektar Therapeutics (NASDAQ:NKTR) shares increased by 89.89% to $1.01. The current volume of 138.1 million shares is 4109.5% of Nektar Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $191.3 million. Tabula Rasa HealthCare (NASDAQ:TRHC) stock increased by 30.84% to $10.24. Trading volume for Tabula Rasa Hea
8/7/23 1:30:56 PM ET
$ACGN
$BIMI
$ENVB
$INFI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations

Why Aceragen (ACGN) Stock Is Down 30% Today

Chat with this insight

Recent Analyst Ratings for $ACGN

$ACGN Press Releases

Fastest customizable press release news feed in the world

Aceragen, Inc. to Delist from The Nasdaq Stock Market

Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study

$ACGN Market Insights

Live Market Insights

12 Health Care Stocks Moving In Wednesday's After-Market Session

Axogen shares are trading lower after the company reported worse-than-expected Q2 revenue results and maintained FY23 revenue guidance.

12 Health Care Stocks Moving In Monday's Intraday Session

Recent Analyst Ratings for
$ACGN

$ACGN
Press Releases

$ACGN
Market Insights